AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17404369
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy alone (66 Gy of chest radiotherapy with carboplatin AUC 2 and paclitaxel 50 mg/m2 weekly)
Trial: 15798610
Drug: Intravenous fibrinolysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fibrinolysis (IVF) with urokinase 900,000 units
Trial: 5484103
Drug: High-arousal group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-arousal group (exposed to infantile oral objects)
Trial: 30915458
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (CAS4, CAS5, CAS6)
Trial: 26453108
Drug: Step III
RxNorm normalized name: STEP 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step III analgesics
Trial: 23860019
Drug: Real PKP
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real PKP treatment (1 treatment weekly for 5 weeks)
Trial: 23860019
Drug: Sham PKP
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham PKP treatment (1 treatment weekly for 5 weeks)
Trial: 19170232
Drug: Low-dose CAF
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CAF (300 mg/m(2), 30 mg/m(2), 300 x 2 mg/m(2) over 4 cycles)
Trial: 19170232
Drug: Standard-dose CAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose CAF (400 mg/m(2), 40 mg/m(2), 400 x 2 mg/m(2) over 6 cycles)
Trial: 19170232
Drug: High-dose CAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose CAF (600 mg/m(2), 60 mg/m(2), 600 x 2 mg/m(2) over 4 cycles)
Trial: 16515705
Drug: Alternating ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alternating ibuprofen (10 mg/kg) and acetaminophen (15 mg/kg)
Trial: 16515705
Drug: Alternating ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alternating ibuprofen and acetaminophen
Trial: 11258130
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg diclofenac-sodium by short time i.v.-infusion (30 min)
Trial: 9190982
Drug: ip Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ip Carboplatin 400 mg/m2 Day 1 q 28 days (CBDCA)
Trial: 9190982
Drug: ip interferon‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ip interferon‐alpha 25 x 10(6) U Day 1 + ip carboplatin 400 mg/m2 Day 2 q 28 days (CBDCA + IFN)
Trial: 29485527
Drug: Antidepressant use
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant use among women with moderate to severe depressive symptoms
Trial: 15848601
Drug: Losartan (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (25 to 50 mg/day)
Trial: 15848601
Drug: Candesartan (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (4 to 8 mg/day)
Trial: 15848601
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 to 40 mg/day)
Trial: 10527967
Drug: Mutational screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mutational screening of prostaglandin F2alpha receptor
Trial: 8577020
Drug: Drinks with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinks with increasing carbohydrate content (45 to 90 g/L) at constant osmolarity (330 mOsm/kg)
Trial: 8577020
Drug: Drinks with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinks with constant carbohydrate content (60 g/L) but varying osmolarity (243 to 374 mOsm/kg)
Trial: 22832887
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment with a stainless steel 3.5‐mm reconstruction plate
Trial: 15728051
Drug: Large volume
RxNorm normalized name: NEBULIZER,LARGE VOLUME #1770
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large volume infusion (2 mL/kg per hour fasting) of compound sodium lactate solution
Trial: 15728051
Drug: Small volume
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small volume infusion (3 mL/kg) of compound sodium lactate solution
Trial: 3041358
Drug: Sandoglobulin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandoglobulin (500 mg/kg)
Trial: 17956570
Drug: Implant exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant exposure
Trial: 12115019
Drug: Oral activated
RxNorm normalized name: activated charcoal Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral activated charcoal (50 g)
Trial: 9385113
Drug: Treatment under
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment under non-identifiable assumptions
Trial: 9385113
Drug: Treatment effect
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment effect estimation
Trial: 2571864
Drug: Porcine insulin
RxNorm normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Porcine insulin (50 mU/kg per hour)
Trial: 2571864
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin (50 mU/kg per hour)
Trial: 354938
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Clonazepam and Baclofen
Trial: 30564806
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading of dental implants with SLActive surface
Trial: 30564806
Drug: Early loading
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early loading of dental implants with SLActive surface
Trial: 18201432
Drug: Traditional aerosol
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional aerosol therapy (Group A)
Trial: 18201432
Drug: Abbreviated aerosol
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abbreviated aerosol therapy with new spacer mouth mask (Group B)
Trial: 15716985
Drug: Phenobarbital (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (5 mg/kg/day for first 3 days)
Trial: 12093850
Drug: Day 5
RxNorm normalized name: One-A-Day 50+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 5 embryo transfer (after culture in sequential media)
Trial: 10069787
Drug: 10 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL/kg body weight of 0.9% saline infusion
Trial: 10069787
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion in normal subjects
Trial: 7568536
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (individual)
Trial: 2208537
Drug: Lidocaine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (0.2 ml one per cent intradermally)
Trial: 156069
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of chemotherapeutic agents (15 drugs)
Trial: 28294174
Drug: EPA+DHA (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA+DHA (4 g/day)
Trial: 24497661
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for insomnia (CBT‐I)
Trial: 19335986
Drug: Capsule metadoxine
RxNorm normalized name: metadoxine
DrugBank: Metadoxine (DB16554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule metadoxine 500mg tid po
Trial: 15321816
Drug: AB-yogurt (10^7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AB-yogurt (10^7 colony-forming units of both Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12/mL) twice daily after a meal for 6 weeks
Trial: 30064713
Drug: DCCT intensive
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DCCT intensive therapy
Trial: 29409289
Drug: Suture-tape augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suture-tape augmentation
Trial: 26834213
Drug: Baricitinib 8
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baricitinib 8 mg
Trial: 26800231
Drug: Baricitinib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib (all doses except 2 mg)
Trial: 26800231
Drug: Baricitinib 8
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baricitinib 8 mg and 10 mg
Trial: 22451206
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of liquefied brain tissue (5 days per week)
Trial: 7753339
Drug: Naloxone (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (125 micrograms/kg) and AVP (10 units) combined administration
Trial: 7753339
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg) with naloxone and AVP
Trial: 27053335
Drug: Thiopental sodium
RxNorm normalized name: Thiopental Sodium
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopental sodium (25 mg/kg administered rectally)
Trial: 26141305
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of r-hFSH plus r-hLH (Pergoveris)
Trial: 26141305
Drug: r-hFSH monotherapy
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-hFSH monotherapy (GONAL-f)
Trial: 23358057
Drug: Supportive text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive text messages delivered twice daily for three months
Trial: 21333087
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion during pressure support ventilation
Trial: 21333087
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion during pressure support ventilation
Trial: 15606399
Drug: Ultrase MT12
RxNorm normalized name: Ultrase MT12 Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrase MT12 (12,000 lipase units per capsule)
Trial: 15606399
Drug: Ultrase MT20
RxNorm normalized name: Ultrase MT20 Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrase MT20 (20,000 lipase units per capsule)
Trial: 11416689
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of low-dose aspirin, calcium, or other dietary supplements for the prevention of pre-eclampsia
Trial: 7983226
Drug: Desensitization treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desensitization treatment to lessen dietary restraint anxiety
Trial: 16200335
Drug: Metformin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1 g/day)
Trial: 26004162
Drug: Goserelin (GnRHa)
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin (GnRHa) 3.6 mg implant
Trial: 23615868
Drug: GXR and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GXR and LDX in combination
Trial: 17111469
Drug: Spinal hyperbaric
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal hyperbaric ropivacaine 10.5 mg
Trial: 17111469
Drug: Spinal hyperbaric
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal hyperbaric ropivacaine 12 mg
Trial: 17111469
Drug: Spinal hyperbaric
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal hyperbaric ropivacaine 13.5 mg
Trial: 17111469
Drug: Spinal hyperbaric
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal hyperbaric ropivacaine 15 mg
Trial: 11182337
Drug: Neoadjuvant estramustine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant estramustine (10 mg/kg/day) and etoposide (50 mg/m2/day) for three cycles, followed by radical prostatectomy.
Trial: 11182337
Drug: Neoadjuvant estramustine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant estramustine and etoposide treatment.
Trial: 11182337
Drug: Neoadjuvant estramustine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant estramustine and etoposide treatment followed by radical prostatectomy.
Trial: 9216132
Drug: Closed-loop drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop drug infusion using arbutamine
Trial: 3524307
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg orally and metoclopramide 10 mg intravenously
Trial: 3524307
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg orally and metoclopramide 20 mg intravenously
Trial: 27093976
Drug: Pixantrone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pixantrone 50 mg/m(2) intravenously combined with rituximab 375 mg/m(2) intravenously on day 1, for up to six cycles.
Trial: 27093976
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m(2) intravenously combined with rituximab 375 mg/m(2) intravenously on day 1, for up to six cycles.
Trial: 12938827
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 mg at bedtime
Trial: 10732179
Drug: Computer-aided treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-aided treatment (high technology)
Trial: 10732179
Drug: Traditional brush
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional brush machine treatment (low technology)
Trial: 1633517
Drug: Total paracentesis
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total paracentesis plus intravenous albumin infusion
Trial: 31783136
Drug: Sheng-Hua-Tang (SHT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sheng-Hua-Tang (SHT) 200 mg/kg orally for seven consecutive days
Trial: 31751400
Drug: Community-based action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based action teams to change social norms on gender and violence; specific dosage and duration not mentioned.
Trial: 28903842
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment on first postoperative day
Trial: 25649209
Drug: QMF149 (indacaterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QMF149 (indacaterol maleate 500 µg/MF 400 µg)
Trial: 25649209
Drug: MF (400 µg)
RxNorm normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF (400 µg)
Trial: 22584133
Drug: Insulin suspension
RxNorm normalized name: Insulin Suspension Isophane (NPH) (Recombinant)
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin suspension activated by the LGS function
Trial: 17383995
Drug: Intravenous dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dopamine (5 microg/kg/min)
Trial: 17383995
Drug: Intravenous dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dopamine (10 microg/kg/min)
Trial: 11768276
Drug: Individually tailored
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually tailored treatment (n = 38)
Trial: 25321951
Drug: Wavefront-guided (WFG)
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wavefront-guided (WFG) PRK treatment
Trial: 25321951
Drug: Wavefront-optimized (WFO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wavefront-optimized (WFO) PRK treatment
Trial: 22716199
Drug: Patient-centered collaborative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-centered collaborative care (CC)
Trial: 22716199
Drug: Standard collaborative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard collaborative care (CC)
Trial: 12685616
Drug: niacin ER/lovastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: niacin ER/lovastatin 2,000/40 mg
Trial: 12685616
Drug: lovastatin 40
RxNorm normalized name: lovastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lovastatin 40 mg
Trial: 11552018
Drug: OXC 2400
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OXC 2400 mg/day
Trial: 11552018
Drug: OXC 300
RxNorm normalized name: oxcarbazepine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXC 300 mg/day
Trial: 1587075
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg sustained-release fenfluramine plus 15 mg phentermine resin
Trial: 1587075
Drug: Initial receipt
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial receipt of medication (fenfluramine plus phentermine)
Trial: 1587075
Drug: Active medication
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active medication (fenfluramine plus phentermine)
Trial: 4028808
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg pentoxifylline ('Trental' 400) 3 times daily for 8 weeks
Trial: 4028808
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg co-dergocrine mesylate 3 times daily for 8 weeks
Trial: 26924405
Drug: Ablative fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative fractional carbon dioxide laser combined with intradermal platelet-rich plasma treatment
Trial: 26924405
Drug: Ablative fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative fractional carbon dioxide laser with intradermal normal saline
Trial: 19874728
Drug: Antihistamines, antihistamine‐decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamines, antihistamine‐decongestant combinations, guaifenesin
Trial: 19874728
Drug: Antihistamines, decongestants,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamines, decongestants, DM, or combinations
Trial: 14612894
Drug: Gemcitabine (fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (fixed dose rate schedule)
Trial: 11087784
Drug: Sodium dichloroacetate
RxNorm normalized name: sodium dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium dichloroacetate (single infusion)
Trial: 25273343
Drug: Bevacizumab and
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab and capecitabine (bevacizumab 15 mg/kg on day 1; capecitabine 1000 mg/m2 twice per day on days 1-14, every 3 weeks)
Trial: 25273343
Drug: Bevacizumab only
RxNorm normalized name: Bevacizumab only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab only (15 mg/kg on day 1)
Trial: 19934097
Drug: Conventional catheters
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional catheters (CC)
Trial: 15767470
Drug: Olmesartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan (40 mg) for 12 weeks
Trial: 15767470
Drug: Irbesartan (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (300 mg) for 12 weeks
Trial: 11272364
Drug: Intracoronary radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary radiation therapy using the Galileo Centering Catheter
Trial: 1660514
Drug: Human alpha-ANP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human alpha-ANP infusion at 0.01 micrograms/kg per min
Trial: 1660514
Drug: Placebo ANP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ANP infusion
Trial: 27842383
Drug: Ledipasvir (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir (90 mg) and sofosbuvir (400 mg) for 12 weeks
Trial: 27842383
Drug: Ledipasvir (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir (90 mg) and sofosbuvir (400 mg) for 24 weeks
Trial: 17709451
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (5 mg) and vitamin B-12 (1.25 mg) supplementation
Trial: 8733881
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of antithyroid antibodies
Trial: 7159691
Drug: Chlorbutol (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorbutol (oral administration)